5-Fluorouracil Encapsulated Plga Nanoparticles For The Treatment Of Lung Cancer

Non-Small Cell Lung Cancer (NSCLC) is accounted for almost 84% of all types of lung cancer diagnosed so far. The NSCLC is targeting many peoples worldwide every year, irrespective of their gender. 5-fluorouracil (5-FU) is an anticancer drug with uracil analog. This drug has tendencies to annihilate different tumor cells. But the biggest challenge of 5-FU is as: it gets metabolize very fast in the blood, which ultimately leads to lower anticancer activities. The main objective of this research was to prepare 15% w/w 5-FU loaded nanoparticles which has potential anti lung cancer activity. In this experiment, an attempt was made to prepare 5-FU loaded PLGA nanoparticles and subsequently observed the effect of PLGA molecular weight, PLGA loading, sonication time on the 15% w/w 5-FU loaded nanoparticles cytotoxic effect against A549 Isogenic Cell line (Human). In this experiment, two things are more evident; first, PLGA has a significant impact on 5-FU release due to the higher degradation and rate of PLGA diffusion in nanoparticle solution; second, nanoparticles having a larger surface area and smaller particle size has lower IC50 value. In conclusion, 5-FU encapsulated PLGA nanoparticles was prepared successfully using solvent evaporation method and anticancer activity of the nanoparticles were tested against A549 isogenic cell line, which suggest that the prepared nanoparticles was found to be a good candidate for lung cancer treatment.